Abstract 2736: Analysis of ROS concentration in serous ovarian carcinoma

Abstract Serous ovarian cancer is the most malignant form of cancer affecting the female reproductive tract. Early detection is associated with 90% five year survival however, current screening tools are not sensitive enough to detect ovarian cancer at early stages. Thus, there remains a critical need for advanced diagnositic tools for early detection and improved prognosis. An accumulation of ROS compounds coupled with increased oxidative stress over time can be deleterious and has been implicated in many human diseases including serous ovarian cancer. Evalution of the ROS concentration in different stages of serous ovarian cancer could be helpful in understanding of the different signaling pathways that may be involved in the transformations of ovarian tumor tissue phenotype. In this study the production of ROS compounds were evaluated in the mitochondria as a caustic of oxidative stress that involve in the transformations of serous ovarian carcinoma. Through the use of a fluorogenic probe, dichlorodihydrofluorescin (DCFH-DiOxyQ) that reacts with the free radicals in a sample, cumulative level of ROS concentrations among stages of serous ovarian carcinoma were detected. Results revealed an increase of 25% ROS fluorescence in the malignant stages compared to normal/surrounding tissues samples. Additionally there was a notably higher ROS concentration in the malignant stages compared to the borderline tissue samples. Results from this study indicate an exponential increase in the levels of ROS from the benign to malignant stages of the disease, suggesting that cumulative ROS levels from early to late of stages may be involved in the progressive stages of the serous ovarian disease type. Citation Format: Shakeria L. Cohen, Sharifeh Mehbari, Edward E. Partridge, Felix Aikhionbare. Analysis of ROS concentration in serous ovarian carcinoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2736. doi:10.1158/1538-7445.AM2015-2736